Navigation Links
Close Scrutiny Needed as First Stem Cell Grants Offered to For-Profit Companies, Consumers Say

SANTA MONICA, Calif., Nov. 30 /PRNewswire-USNewswire/ -- California's stem cell agency is inviting for-profit companies to apply for research grants for the first time, the Foundation for Taxpayer and Consumer Rights (FTCR) noted today and the non-partisan, non-profit consumer advocacy organization vowed to scrutinize the awards process to prevent abuse.

The California Institute for Regenerative Medicine (CIRM) has just issued calls for applications for two types of grants. CIRM said it planned to fund up to 20 six-month disease team planning grants for a total of $1.1 million. The stem cell agency has also ear marked $25 million for up to 16 three-year grants to develop new stem cell lines.

"We've already seen an example of an improper attempt by a stem cell board member to influence an award to his non-profit research institution," said John M. Simpson, FTCR's Stem Cell Project Director. "The possibility of abuse is even greater when the biotech industry goes after the money."

Researchers from both universities and companies will compete head-to-head for the grants. CIRM staff have vowed that only the quality of the science in the proposed projects will determine who gets the money. The grants will be awarded in the spring.

So far CIRM has awarded about $210 million in research, training and facilities grants. All that money has gone to universities and non-profit research institutions. When Californians approved Proposition 71 funding the state's $6-billion stem cell project, they approved giving money to companies as well as universities and research institutions.

Companies have not been able to apply for grants because the Intellectual Property (IP) regulations governing who controls any discoveries made with CIRM-funded research had not been created for businesses. Those IP rules are expected to be approved at the stem cell oversight board's December meeting.

"Biotech companies will clearly play an important role in stem cell research," said Simpson. "Californians voted to allow them to seek CIRM funds, but at the same time they didn't authorize a blank check for biotech. We will continue to watch CIRM and the oversight committee closely and work to ensure that those who are paying for this research -- the people of California -- have affordable access to any discoveries that are made."

This week Controller John Chiang announced that he planned to audit CIRM. He also asked the Fair Political Practices Commission to investigate board member John Reed's intervention in a grant application from the Burnham Institute for Medical Research where he is president. "I am delighted to see Controller Chiang exercising his oversight responsibility so effectively," said Simpson.

FTCR's Stem Cell Oversight and Accountability Project is working to ensure that California's landmark stem cell research program offers accessible and affordable cures and treatments to the taxpayers who have funded it. The program will award $3 billion in grants over a decade. Bond financing charges mean the project, the largest source of stem cell research funding in the world, will cost California taxpayers $6 billion.

The Foundation for Taxpayer and Consumer Rights is California's leading non-profit and non-partisan consumer watchdog group. For more information visit us on the web at:

SOURCE Foundation for Taxpayer and Consumer Rights
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Experiments Get Close to Out-of-Body Experience
2. HEI, Inc. Closes on Sale of RFID Division Assets
3. PSI Brings its Pioneering Efforts to a Close
4. Acute lung injury patients one-third less likely to die in closed model ICUs
5. Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
6. Bally Total Fitness Emerges From Chapter 11 and Closes Transaction with Harbinger Capital Partners Funds
7. Nexia Closes Acquisition of Green Endeavors; Landis Salons On Track to Generate Revenues of $2.2 Million in 2007
8. Actor Joe Pantoliano Discloses Depression; Talks About His Latest Movie and His Sensitive Side
9. Stryker Discloses Informal Inquiry Made by United States Securities and Exchange Commission
10. MediKeeper Closes Series A Financing Round with PacifiCap as Lead Investor
11. Packard Childrens Hospital Opens New South Bay Specialty Clinic Bringing Specialty Care Close to Home
Post Your Comments:
(Date:6/27/2016)... Viejo, California (PRWEB) , ... June 27, 2016 , ... ... are fully customizable inside of Final Cut Pro X," said Christina Austin - CEO ... another unique style. Final Cut Pro X users can now reveal the ...
(Date:6/27/2016)... ... June 27, 2016 , ... ... industry today announced its strategic partnership with Connance, a healthcare industry leader ... two companies’ proven, proprietary technology combine to provide health systems, hospitals and ...
(Date:6/27/2016)... ... , ... recently awarded their highest five-star rating to Best Buy Eyeglasses, ... the United States and Canada wear eyeglasses. Once considered to be a purely functional ... a fashion statement. Even celebrities use glasses as a way of creating an iconic ...
(Date:6/26/2016)... ... 2016 , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment ... Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This ... of the world’s leading providers of cereal and other breakfast foods. Its residents often ...
(Date:6/26/2016)... ... ... PawPaws brand pet supplements owned by Whole Health Supply is ... of felines. The formula is all-natural and is made from Chinese herbs that have ... Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root Extract ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: